Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental?

03 September 2021: Articles

Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction

Khezar Syed ^A* , Haseeb Chaudhary ^A , Anthony Donato ^E

DOI: 10.12659/AJCR.933397

Am J Case Rep 2021; 22:e933397

Table 1. Lab work and thrombophilia work-up.

Hemoglobin	15.7 g/dL	PT	14.8 sec (11.7–14.2 sec)
WBC	17.9×10E3/uL	INR	1.2
Platelets	255×10E3/uL	APTT	30.5 sec (23.1–34.3 sec)
Sodium	142	Potassium	3.9
HCO3	7.1	Chloride	99
Creatinine	134.4 umol/L (1.52 mg/dL)	BUN	8.93 mmol/L (25 mg/dL)
Magnesium	2.9	Calcium	10.2
Glucose	19.25 mmol/L (347 mg/dL)	Lactic Acid	28.3 mmol/L
COVID-19 RT-PCR	Negative	Troponin

Rheumatoid factor		Myeloperoxidase ab	0 (0–19 AU/mL)
Factor V Leiden (F5) R506Q Mutation	Negative	Anti-nuclear antibodies	Negative
ANA, Hep-2 Antibody IgG		Angiotensin Converting enzyme	32 (9–67 U/L)
Cardiolipin IgA, IgM, IgG	Negative	Lipoprotein A	32 (≤29 mg/dL)
Prothrombin (F2) G20210A Mutation	Not detected	Anti-neutrophil cytoplasmic antibody IgG
Serine Proteinase 3 AB IgG	0 (0–19 AU/mL)